BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 15843454)

  • 1. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.
    Pallavicini FB; Caporali R; Sarzi-Puttini P; Atzeni F; Bazzani C; Gorla R; Marchesoni A; Favalli EG; Montecucco C
    Autoimmun Rev; 2010 Jan; 9(3):175-80. PubMed ID: 19647103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study.
    Hellgren K; Iliadou A; Rosenquist R; Feltelius N; Backlin C; Enblad G; Askling J; Baecklund E
    Ann Rheum Dis; 2010 Apr; 69(4):654-9. PubMed ID: 19439429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.
    Hellgren K; Smedby KE; Feltelius N; Baecklund E; Askling J
    Arthritis Rheum; 2010 May; 62(5):1252-8. PubMed ID: 20155827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
    Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
    Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
    Raaschou P; Simard JF; Neovius M; Askling J;
    Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
    Olofsson T; Englund M; Saxne T; Jöud A; Jacobsson LT; Geborek P; Allaire S; Petersson IF
    Ann Rheum Dis; 2010 Dec; 69(12):2131-6. PubMed ID: 20693274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
    Ann Rheum Dis; 2007 Oct; 66(10):1339-44. PubMed ID: 17261532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
    Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
    Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.
    Ekström K; Hjalgrim H; Brandt L; Baecklund E; Klareskog L; Ekbom A; Askling J
    Arthritis Rheum; 2003 Apr; 48(4):963-70. PubMed ID: 12687538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.